Amenta, Alison R.,Yilmaz, Atilgan,McKechnie, Beth A.,Fallon, Justin R.
申请号：
AU2011352228
公开号：
AU2011352228B2
申请日:
2011.12.27
申请国别(地区):
AU
年份:
2015
代理人:
摘要：
The present disclosure provides methods for predicting a patient's response to biglycan therapy for diseases or conditions associated with an abnormal level or activity of biglycan； disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC)； disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation, the methods of predicting response comprising determining the level or activity of utrophin protein. Examples of such diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders. This application also provides combination therapeutics, such as a biglycan therapeutic and a utrophin therapeutic.
